Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

Stock Information for Allurion Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Allurion Technologies Inc.

Allurion Advances Plan to Regain Listing Compliance
Allurion Begins Training and On?Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
Allurion Receives U.S. FDA Approval
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.